6-methyl-2-(1-piperidinyl)-6,7-Dihydro-5H-pyrrolo(3,4-d)pyrimidin-5-one | 104966-11-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 6-methyl-2-(1-piperidinyl)-6,7-Dihydro-5H-pyrrolo(3,4-d)pyrimidin-5-one
• 英文别名: 6-methyl-2-piperidin-1-yl-7H-pyrrolo[3,4-d]pyrimidin-5-one
• CAS: 104966-11-2；122113-52-4
• 化学式: C₁₂H₁₆N₄O
• 分子量: 232.28
• InChiKey: YMJJMENUYBRBET-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  49.3
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• Wound-healing agent
  申请人：MITSUI PHARMACEUTICALS, INC.

  公开号：EP0743066A2

  公开（公告）日：1996-11-20

  The present invention provides a method for the screening of a wound-healing agent, which comprises determining a substance to be active as a wound-healing agent on the basis of potentiation or modification of biological activities of a growth and/or differentiation factor, a growth hormone or a cytokine. This invention also provides a wound-healing agent, which comprises as an active ingredient a compound of the following formula (1) or formula (2).

  本发明提供了一种筛选伤口愈合剂的方法，该方法包括根据生长和/或分化因子、生长激素或细胞因子的生物活性的增强或改变来确定一种物质作为伤口愈合剂的活性。本发明还提供了一种伤口愈合剂，其活性成分包括下式（1）或式（2）的化合物。
• USE OF PYRIMIDINE DERIVATIVES FOR COSMETIC PURPOSES
  申请人：DSM IP Assets B.V.

  公开号：EP1890673A1

  公开（公告）日：2008-02-27
• VIGOR ENHANCEMENT VIA ADMINISTRATION OF PYRIMIDINE DERIVATIVES
  申请人：UNIVERSITY OF CENTRAL FLORIDA

  公开号：EP2324023A1

  公开（公告）日：2011-05-25
• COMPOSITIONS FOR TREATING OR DELAYING THE ONSET OF HAIR LOSS
  申请人：University Of Central Florida Research Foundation, Inc.

  公开号：EP2326330B1

  公开（公告）日：2015-01-07
• Vigor Enhancement Via Administration of Pyrimidine Derivatives
  申请人：Sugaya Kiminobu

  公开号：US20080124306A1

  公开（公告）日：2008-05-29

  Disclosed herein are methods for increasing the overall vigor of a subject, and/or vigor of target tissues of a subject. Exemplified herein is the utilization of pyrimidine derivatives which act to stimulate stem cell proliferation. In addition to increasing vigor, such stem cell proliferation agents (SCPA) may be used to enhance and/or improve the outcome of other therapies, and may be used in psychiatric applications. Increasing vigor in subjects is not necessarily targeted to the treatment of a disease, thus, the methods can include administration to clinically healthy animals.